Extended dosing (12 cycles) of adjuvant temozolomide in adults with newly diagnosed high grade gliomas a review of clinical effectiveness, cost-effectiveness, and guidelines
The purpose of this review is to identify the clinical evidence on 12 cycles of adjuvant temozolomide (TMZ) for patients with newly diagnosed high-grade gliomas, and to examine the clinical and costeffectiveness of this extended treatment regimen for these patients
| Main Authors: | , |
|---|---|
| Corporate Authors: | , |
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa
CADTH
2018, February 26, 2018
|
| Series: | CADTH rapid response report: summary with critical appraisal
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The purpose of this review is to identify the clinical evidence on 12 cycles of adjuvant temozolomide (TMZ) for patients with newly diagnosed high-grade gliomas, and to examine the clinical and costeffectiveness of this extended treatment regimen for these patients |
|---|---|
| Item Description: | "Version: 1.0." |
| Physical Description: | 1 PDF file (23 pages) illustration |